HeartBeam Inc. BEAT Archives - Page 3 of 11

TuesdayAug 05, 2025 11:15 am

HeartBeam Inc.’s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics

Two newly issued patents mark a strategic advancement in HeartBeam’s proprietary technology. The first patent protects the company’s credit card–sized, cable-free 3D ECG device designed to capture high-fidelity electrical signals from three noncoplanar directions. The second patent covers the company’s rhythm analysis algorithm by continuously analyzing signal input. HeartBeam (NASDAQ: BEAT), a cardiac technology company, has secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology (https://ibn.fm/6xni4). The company, focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform, now holds more than 20 U.S.…

WednesdayJul 30, 2025 9:00 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Schedules Aug. 13 Call to Discuss Q2 Results and Provide Business Updates

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care with personalized insights, will hold a conference call Aug. 13, 2025, at 4:30 p.m. Eastern to discuss second-quarter results for the period ended June 30, 2025. The company will also provide updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. CEO Robert Eno and CFO Timothy Cruickshank will host the call, followed by a question-and-answer session. To view the full press release, visit https://ibn.fm/CUZGt About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The…

TuesdayJul 22, 2025 9:10 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Wins 2025 Innovation Award for Remote Cardiac Diagnostics

HeartBeam (NASDAQ: BEAT), a medical technology company advancing personalized cardiac care, has received the Innovation Award in Remote Cardiac Diagnostics from the 2025 Medical Device Network Excellence Awards. The honor recognizes HeartBeam’s FDA-cleared 3D ECG technology, which enables clinical-grade arrhythmia diagnostics in non-clinical settings via a compact, cable-free device. The synthesized 12-lead ECG software is under FDA review, with commercialization planned upon clearance. This award adds to HeartBeam’s growing list of accolades for its leadership in remote cardiac care. To view the full press release, visit https://ibn.fm/la16M About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac…

TuesdayJul 08, 2025 3:03 pm

QualityStocksNewsBreaks – Why HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. “HeartBeam’s vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, accuracy of conventional 12-lead ECGs for arrhythmia detection, but also unlocks future capabilities in ischemia detection, AI-assisted analysis, and longitudinal cardiac trend tracking,” reads a recent article. “As it approaches commercialization, HeartBeam is executing a multi-phase go-to-market strategy with initial U.S. rollout plans and a focus…

TuesdayJun 17, 2025 9:00 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) and AccurKardia Join Forces to Advance Remote Cardiac Monitoring

HeartBeam to integrate AccurECG(TM), AccurKardia’s FDA-cleared ECG analysis software Collaboration enhances HeartBeam’s commercial offering with automated arrhythmia insights Combined platform aims to improve cardiac care access and speed time to diagnosis HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with AccurKardia, a leader in automated ECG diagnostics, to integrate its FDA-cleared AccurECG(TM) software into HeartBeam’s cable-free, credit card-sized 3D ECG device. The partnership unites two innovators in ambulatory cardiac monitoring to create a more scalable, accessible solution for arrhythmia detection and management. HeartBeam’s device captures electrical signals in three non-coplanar directions and synthesizes them into a 12-lead ECG for remote use.…

MondayJun 16, 2025 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam has developed the first cable-free system capable of synthesizing a 12-lead ECG from 3D, non-coplanar electrical signals captured in real time. Patients can have the HeartBeam System with them at all times, ready to record an ECG in 30 seconds at home or anywhere when they feel symptoms to reduce delays in care. The HeartBeam System is now FDA cleared for arrhythmia assessment, with additional FDA review underway for its 12-lead ECG synthesis software for the same indication. A recent partnership with AccurKardia enhances HeartBeam’s arrhythmia solution with an FDA-cleared automated rhythm interpretation software. HeartBeam holds 20 issued patents,…

MondayJun 16, 2025 9:00 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) VALID-ECG Study Confirms Diagnostic Accuracy of Synthesized 12-Lead ECG

HeartBeam’s credit card-sized device demonstrated 93.4% diagnostic agreement with standard ECGs VALID-ECG study results presented at Heart Rhythm Society conference Company eyes U.S. commercialization pending FDA clearance HeartBeam (NASDAQ: BEAT) announced its synthesized 12-lead ECG met clinical endpoints in the VALID-ECG pivotal study, achieving 93.4% diagnostic agreement with standard ECGs for arrhythmia assessment. The findings, presented by Dr. Thomas Deering of Piedmont Heart Institute at the Heart Rhythm Society’s annual meeting in San Diego, validate HeartBeam’s compact, patient-friendly ECG technology. The study compared ECG intervals and amplitudes between HeartBeam’s synthesized output and simultaneously collected standard ECGs in 198 patients across…

WednesdayMay 14, 2025 9:30 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Hits FDA Milestone and Expands Strategic Partnerships in Q1 Update

HeartBeam (NASDAQ: BEAT) reported Q1 2025 results highlighted by successful completion of the VALID-ECG pivotal study, supporting its 510(k) submission for 12-lead ECG synthesis software and confirming productive ongoing FDA discussions. The company launched an Early Access Program, signed a strategic partnership with AccurKardia to integrate its FDA-cleared AccurECG(TM) software, added two new U.S. patents to bring its IP total to 20, appointed CEO Robert Eno to its board, and raised $11.5 million through a public offering to support commercialization plans. To view the full press release, visit https://ibn.fm/06UMF About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming…

ThursdayMay 01, 2025 9:40 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Report Q1 2025 Results and Provide Business Update on May 13

HeartBeam (NASDAQ: BEAT) will host a conference call on May 13 at 4:30 p.m. Eastern to discuss financial results for the first quarter ended March 31, 2025. CEO Robert Eno and CFO Timothy Cruickshank will lead the call, which will include updates on regulatory progress, commercial-readiness efforts, and upcoming milestones. A corresponding press release and presentation will be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/MXmYz About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the…

TuesdayApr 29, 2025 9:40 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Positive VALID-ECG Study Results Supporting 12-Lead ECG Technology

HeartBeam (NASDAQ: BEAT) announced that its synthesized 12-lead ECG technology met clinical endpoints in the VALID-ECG pivotal study, achieving a 93.4% diagnostic agreement with standard 12-lead ECGs for arrhythmia assessment. Results were presented by Dr. Thomas Deering of Piedmont Heart Institute during the Heart Rhythm Society’s annual conference. HeartBeam’s 3D ECG technology, designed to fit into a credit card-sized device, aims to bring hospital-grade cardiac insights to patients anywhere, with commercialization planned following anticipated FDA clearance. To view the full press release, visit https://ibn.fm/ABvdX About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac…

Site Search

Company Search

Tag: HeartBeam Inc. BEAT